Safer HLA mismatch transplantation

Abstract

In this issue of Blood, Kornblit et al report on their multicenter phase 2 clinical trial (NCT01251575) investigating a new way of undertaking HLA mismatched transplantation with results that suggest a significantly improved safety profile and generally low disease relapse.1 This protocol seems to be a promising and viable new clinical option for many patients who might not otherwise receive a transplant (see figure).